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esponsibility of InstAbstract This paper reports the development and validation of an assay for ifenprodil based on liquid
chromatography–tandem mass spectrometry (LC–MS/MS) and its application to a pharmacokinetic study
involving single and multiple intravenous infusions to healthy Chinese volunteers. After sample preparation
of plasma by liquid–liquid extraction with ethyl acetate, the analyte and internal standard, urapidil, were
separated by reversed phase chromatography in a run time of 4 min and detected by positive ion electrospray
ionization followed by multiple reaction monitoring of the precursor-to-product ion transitions at m/z
326.2-308.1 for ifenprodil and m/z 388.4-205.3 for IS. The assay was linear in the concentration range
0.2–50.0 ng/mL with recovery 476.4%. In the pharmacokinetic study of single intravenous infusions of
5, 10 and 15 mg ifenprodil, peak plasma concentrations and areas under the plasma concentration–time
curve were both linearly related to dose. In the pharmacokinetic study of multiple once daily intravenous
infusions of 10 mg ifenprodil for 7 days, pharmacokinetic parameters were similar to those after the single
dose showing that ifenprodil does not accumulate on repeated administration.
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a pharmacokinetic study in healthy Chinese volunteers 1811. Introduction
Ifenprodil [(1RS, 2SR)-4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypro-
pyl]phenol hemi-(2R,3R)-tartrate] (Fig. 1A) is a new class of N-
methyl-D-aspartate (NMDA) receptor antagonist that selectively
inhibits NMDA receptors containing the NR2B subunit1,2. The drug
has been widely used in the treatment of cerebrovascular diseases
and peripheral arterial obliterative disease3–5. However, pharmaco-
kinetic studies of ifenprodil are limited to one involving a single dose
administration6 and there is no literature reporting the pharmacoki-
netics of ifenprodil after multiple doses. The aim of the present study
was to develop and validate an assay for ifenprodil based on liquid
chromatography–tandem mass spectrometry (LC–MS/MS)7 and
apply it to a pharmacokinetic study of ifenprodil involving single
and multiple intravenous infusions to healthy Chinese volunteers.
Determination of ifenprodil by LC–MS/MS and its application to2. Materials and methods
2.1. Reagents and materials
Ifenprodil tartrate for injection and ifenprodil reference standard
(purity 98.7%) were obtained from Sihuan Kebao Pharmaceutical
Co., Ltd. (Bejing, China). Urapidil for use as internal standard (IS)
was purchased from the National Institute for the Control of
Pharmaceutical and Biological Products (Beijing, China). HPLC
grade methanol was purchased from Fisher Scientiﬁc (Pittsburgh,
PA, USA). Water was deionized and puriﬁed using a Milli-Q
Water Puriﬁcation System (Millipore, Bedford, MA, USA). All
other chemicals and reagents were of analytical grade and used as
received. Drug-free human plasma from healthy volunteers was
kindly provided by the Blood Center of Xijing Hospital (Shanxi,
China) and was stored at −20 1C until use.
2.2. Instrumentation
LC–MS/MS was performed using an Agilent 1200 series HPLC
equipped with a Spursil C18-EP column (150 mm 2.1 mm i.d.,
3 mm) maintained at 35 1C and an Agilent 6410 Triple Quadrupole
mass spectrometer equipped with an electrospray ionization (ESI)
source (Agilent Technologies, USA) operating in the positiveFigure 1 Chemical structures of (A) ifenprodil and (B) urapidil.ionization mode. All data were acquired and processed using
Agilent 6410 Quantitative Analysis processing software.
2.3. Preparation of the calibration standards and quality
control (QC) samples
A stock solution of ifenprodil was prepared in methanol and serially
diluted with methanol to give standard solutions with concentrations
of 0.01, 0.1, 1.0, 10.0 and 100.0 mg/mL. In a similar manner, an IS
working solution (203.2 ng/mL) was prepared by diluting a stock
solution of urapidil (101.6 mg/mL). All solutions were kept at
−20 1C until use. Calibration standards (0.20, 0.50, 1.0, 2.0, 5.0,
10.0, 20.0 and 50.0 ng/mL) and QC samples (0.5, 4 and 40 ng/mL)
were prepared by spiking 0.5 mL blank plasma samples with
different volumes of working solutions.
2.4. Sample preparation
Frozen human plasma samples were thawed at ambient tempera-
ture and 0.5 mL aliquots mixed with 50 mL IS working solution.
The mixture was then subjected to liquid–liquid extraction (LLE)
by vortex-mixing for 3 min with 4 mL ethyl acetate and centrifu-
ging at 4000 rpm for 10 min. The organic layer was removed and
evaporated under a stream of nitrogen gas at 40 1C. The residue
was reconstituted in 120 mL mobile phase, vortex-mixed for 1 min,
centrifuged at 16,000 rpm for 3 min and 5 mL of supernatant
injected into the LC–MS/MS system.
2.5. LC–MS/MS conditions
The mobile phase was methanol–10 mM ammonium acetate
solution (90:10, v/v) delivered at a ﬂow rate of 0.2 mL/min.
Detection was by multiple reaction monitoring (MRM) of the
precursor-to-product ion transitions at m/z 326.2-308.1 for
ifenprodil and m/z 388.4-205.3 for IS. Optimized MS parameters
were as follows: nebulizer pressure 40 psi; drying gas temperature
350 1C; dry gas ﬂow rate 10 L/min; dwell time per transition
200 ms; EMV 200 V; fragmentor voltages 140 V (ifenprodil) and
150 V (IS); collision energies 19 eV (ifenprodil) and 45 eV (IS).
2.6. Assay validation
Assay validation was carried out according to the USFDA guide-
lines8. Speciﬁcity was assessed by comparing the chromatograms of
six different batches of blank human plasma with the corresponding
spiked plasma. Linearity was determined by weighted (1/C2) least-
squares linear regression of calibration curves based on eight
calibration standards prepared from three batches of plasma. The
acceptance criteria for the calibration curve were a correlation
coefﬁcient (r) ≥ 0.99 and that each back-calculated concentration
was within 15% of the nominal value. The lower limit of quantitation
(LLOQ) was deﬁned as the lowest concentration on the calibration
curve at which the precision (as relative standard deviation, RSD)
was 20% and accuracy (as relative error, RE) was 720%. Precision
and accuracy of the method were determined by assay of 5 replicates
of QC samples on three validation days. Intra- and inter-batch
precisions (as RSD calculated by one-way analysis of variance) were
required to beo15% with accuracy (as RE) of715%. Recovery of
ifenprodil was determined by comparing peak areas for ifenprodil in
5 replicates of QC samples with those of blank plasma extracts to
which ifenprodil was added after extraction at corresponding
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areas of ifenprodil in 5 replicates of QC samples with those for the
analyte dissolved in mobile phase. If the peak area ratio iso85% or
4115%, a matrix effect is implied. Stability of ifenprodil was
evaluated in 5 replicates of QC samples stored under the following
conditions: short-term stability at room temperature for 24 h; long-
term stability at −20 1C for 30 days; freeze-thaw stability after 3
freeze-thaw cycles. Post-preparative stability of processed samples
was also assessed after storage at room temperature for 20 h.
2.7. Pharmacokinetic study
The pharmacokinetics of ifenprodil were determined after intrave-
nous infusions of ifenprodil tartrate for injection to healthy
Chinese volunteers in accordance with the Declaration of Helsinki
(2008) for biomedical research involving human subjects and
Good Clinical Practice. The protocol and associated informed
consent statements were reviewed and approved by the Committee
on Human Rights Related to Human Experimentation at Xijing
Hospital. All volunteers signed the informed consent statements.
Thirty healthy Chinese healthy subjects (15 males, 15 females
aged 29–40, body weight 56–68 kg) were included in the study.
They had no history of cardiovascular, hepatic, renal, gastrointest-
inal, hematologic, nervous, or any acute or chronic diseases or
drug allergy, and were not allowed to take drugs during the 2
weeks before the study. Physical examination and laboratory tests
showed no abnormal ﬁndings. For the single dose study, subjects
were randomly divided into three groups A, B and C (5 males,
5 females per group) and after an overnight fast were administered
over 30 min single intravenous infusions containing 5 mg, 10 mg
and 15 mg ifenprodil tartrate for injection diluted in 100 mL water
for injection, respectively. Water intake was allowed 2 h post-doseFigure 2 Full-scan positive product ion mass spectra of (A) precursor io
(D) product ion of IS.and standard meals were provided at 4 h and 10 h post-dose.
The subjects were required to refrain from smoking, alcohol,
caffeine and strenuous exercise during the study and were under
direct medical supervision at the study site. Blood samples (4 mL)
were collected at 0 h (pre-dose) and 5, 10, 20, 30 min, 1, 1.5, 2,
2.5, 3.5, 4.5, 6.5, 8.5 and 12.5 h post-dose into heparinized tubes.
Plasma was collected after centrifugation at 4000 rpm for 10 min
and stored at −20 1C until analysis. In the multiple dose study,
Group B received single daily doses of 10 mg ifenprodil tartrate
for injection at 8:00 am on 7 consecutive days. On days 4, 5 and 6,
a venous blood sample (4 mL) was drawn prior to the dose to
determine trough plasma concentrations. On day 7, the pharma-
cokinetics was determined as described for the single dose study.
2.8. Data analysis
Plasma concentration versus time proﬁles were prepared for each
subject and peak plasma concentration (Cmax) and time to Cmax
(Tmax) values obtained by inspection of the data. Other pharma-
cokinetic parameters were calculated by non-compartmental ana-
lysis using WinNonlin software (version 6.2). The elimination rate
constant (k) was calculated as the slope of log plasma concentra-
tion versus time data for measurable points in the elimination
phase. Apparent elimination half-life (t1/2) was calculated as ln 2/k.
Area under the plasma concentration–time curve from time zero
(pre-dose) to the last measurable concentration (AUC0–t) was
calculated using the linear trapezoidal rule. The AUC from time
zero to inﬁnity (AUC0–∞) was calculated as AUC0–t+Ct/k where
Ct is the last measurable drug concentration. The apparent volume
of distribution (Vd) was calculated as Dose/C0, where log C0 was
calculated as the intercept of the log plasma concentration versus
time data for the last four measurable points. Clearance rate (CL)n of ifenprodil; (B) product ion of ifenprodil; (C) precursor of IS and
Figure 3 Typical chromatograms of ifenprodil and IS in human plasma
samples. (A) Blank plasma sample; (B) a blank plasma sample spiked
with ifenprodil (0.20 ng/mL) and IS (20.32 ng/mL); and (C) a plasma
sample obtained from a volunteer at 10 min after intravenous fusion of
5 mg ifenprodil. I: IS; II: ifenprodil.
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concentration (Cssmin), average steady state plasma concentration
(Cav) and area under the plasma concentration–time curve for
steady-state conditions (AUCss) were also calculated.
3. Results and discussion
3.1. Method development
In the present work, sample preparation by LLE was evaluated
using diethyl ether, trichloromethane and ethyl acetate. The latter
produced clean chromatograms for blank plasma and provided a
recovery 474.6%. As regards chromatography, a mobile phase
containing acetonitrile gave higher background noise than metha-
nol. A mixture of methanol–10 mM ammonium acetate solution
(90:10, v/v) was found to provide symmetric peak shapes of
analyte and IS in a short run time. In selecting the IS, several
analogs of ifenprodil were evaluated on the basis that uncertainty
about matrix effects would thereby be largely eliminated. Urapidil
(Fig. 1B) was ﬁnally chosen since it gave similar recovery and
chromatography to those of the analyte. In relation to mass
spectrometry, the analytes and IS yielded major [M+H]+ ions at
m/z 326.2 and 388.4 respectively. The product ion mass spectra
(Fig. 2) show that the most sensitive transitions were at m/z
326.2-308.1 for ifenprodil and m/z 388.4-205.3 for IS.
3.2. Assay validation
Fig. 3 shows typical MRM chromatograms of blank plasma, blank
plasma spiked with ifenprodil and the IS, and a plasma sample from
a volunteer after a single intravenous infusion. The retention times
of ifenprodil and IS were 2.3 and 2.9 min, respectively, and the
assay was free of interference at these times in all plasma samples.
The LLOQ was established at 0.2 ng/mL at which concentration
precision and accuracy were within the required limits (RSD 6.9%,
RE −3%, n¼6). The assay was linear in the range 0.2–50 ng/mL
(r¼0.997) with a typical regression equation of Y¼1.1759C+0.0731.
Precision and accuracy data are summarized in Table 1. The
data demonstrate that the precision and accuracy values were
within acceptable ranges. Recoveries of ifenprodil in low, medium
and high QC samples were 74.677.3%, 78.477.6% and
76.176.6%, respectively. Considering matrix effects, concentra-
tions of low, medium and high QC samples were found to be
95.374.2%, 95.876.9% and 103.676.6%, respectively, of nom-
inal values, indicating matrix effects are not an issue.
Results of stability studies summarized in Table 2 show that no
signiﬁcant degradation of ifenprodil was observed in plasma or in
post-preparative samples under the storage conditions tested.
3.3. Pharmacokinetic study
There were no adverse events observed during the study and the drug
was well tolerated by all volunteers. Mean plasma concentration–
time proﬁles are presented in Figs. 4 and 5 and corresponding non-
compartmental pharmacokinetic parameters are listed in Table 3. The
t1/2, Cmax and AUC after the single intravenous administration are
consistent with previously reported values6. The results show that
Cmax and AUC0–12 are both linearly related to dose over the dose
range studied. The additional steady state parameters were as follows:
Cssmin 0.5370.18 ng/mL; Cav 1.78 70.29 ng/mL; DF 11.7670.65;
AUCss 42.7276.90 ng·h/mL. The t1/2 and AUC for the last dose aresimilar to those after the single-dose (P40.05), indicating that
ifenprodil does not accumulate on repeated administration.
4. Conclusions
A rapid and sensitive assay for ifenprodil in human plasma based on
LC–MS/MS has been developed, validated and successfully applied
to a pharmacokinetic study in healthy volunteers. The results show
ifenprodil does not accumulate on repeated administration.
Table 1 Intra- and inter-batch precision and accuracy for determination of ifenprodil in human plasma.
Concentration (ng/mL) Intra-batch (n¼5) Inter-batch (n¼3)
Measureda (ng/mL) RSD (%) RE (%) Measureda (ng/mL) RSD (%) RE (%)
0.50 0.5370.04 7.4 −4.6 0.5170.04 7.7 −2.9
4.00 3.8970.31 8.0 1.9 3.9470.30 7.5 1.5
40.00 40.172.6 6.4 0.1 41.273.0 7.2 −2.9
aData are expressed as mean7SD.
Table 2 Short-term, post-preparative, freeze-thaw and long-
term stability of ifenprodil in human plasma.
Stability Mean percentage remaining (%)
0.50 4.00 40.00
Short-terma 86.6 113.5 111.8
Post-preparativeb 94.1 104.5 97.4
Freeze-thawc 101.3 108.5 108.0
Long-termd 95.8 105.4 101.0
a24 h, room temperature, n¼5.
b20 h, room temperature, n¼5.
cThree cycles, −20 1C/room temperature, n¼5.
d30 days, −20 1C, n¼5.
Figure 4 Mean plasma concentration–time proﬁles of ifenprodil in
Chinese healthy volunteers following a single intravenous infusion
containing 5, 10 and 15 mg ifenprodil. Data are means7SD, n¼10.
Figure 5 Mean plasma concentration–time proﬁles of ifenprodil in
Chinese healthy volunteers following the ﬁrst and the last dose of intra-
venous infusion containing 10 mg ifenprodil. Data are mens7SD, n¼10.
Table 3 Main pharmacokinetic parameters of ifenprodil
following single intravenous infusions of 5, 10 and 15 mg
ifenprodil tartrate for injection and following single daily
intravenous infusions of 10 mg ifenprodil tartrate for injection
for 7 days to groups of healthy Chinese volunteers.
Parameters 5 mg 10 mg 15 mg 10 mg (ss)
Cmax
(ng/mL)
10.1374.02 19.175.9 28.976.2 20.475.1
Tmax (h) 0.4570.08 0.5070.00 0.4570.08 0.4270.09
t1/2 (h) 3.8770.93 3.6170.97 4.0770.69 4.2571.26
MRT (h) 3.4470.34 3.7270.27 3.5470.16 3.8770.35
AUC0–12
(ng·h/mL)
19.974.8 37.778.5 57.1713.0 41.575.0
AUC0–∞
(ng·h/mL)
21.774.8 41.379.3 63.1713.6 47.078.1
CL (L/h) 241753 254758 249761 218734
Vd (L) 13737566 13067425 15007635 12927241
Data are expressed as mean7SD, n¼10; ss: steady state.
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